1 / 30

Beyond Antibodies

Beyond Antibodies. Sanjeev Kumar Cadila Healthcare Ltd. September 1, 2012. Beyond Antibodies Chapter 1 Conventional Antibodies. Antibodies. Structure. Structure-Function Correlation. Evolution. Terminology. Structure of an Antibody Molecule.

kennan
Télécharger la présentation

Beyond Antibodies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Beyond Antibodies Sanjeev Kumar CadilaHealthcare Ltd. September 1, 2012

  2. Beyond Antibodies Chapter 1 Conventional Antibodies Antibodies Structure Structure-Function Correlation Evolution Terminology

  3. Structure of an Antibody Molecule Nature Reviews Drug Discovery 9, 325-338 (April 2010)

  4. Structure / Function Relationship of an Antibody Molecule Antigen NATURE REVIEWS | Immunology, Vol 10 | MAY 2010 | pp317-327

  5. Evolution of Antibody Generation Platforms over 35+ years Decreasing Immunogenicity Increasing Humanziation Therapeutic and Diagnostic Antibody Sector:-Current Status and Future Directions-March 2006 TRENDS in Biotechnology Vol.23 No.10 October 2005, pp 514-522

  6. Therapeutic Antibodies and Fusion Proteins: Terminology PK/PD Predictions for monoclonal Antibodies, October 09, 2008,Genentech

  7. More than 35 Antibodies Approved by FDA so far and ~250 in clinical development NATURE REVIEWS | Immunology,Vol10 | MAY 2010 | pp 345-52 Therapeutic and Diagnostic Antibody Sector:-Current Status and Future Directions-March 2006

  8. Emerging trends and developments in the mAbs sector, Antibody Engineering & Design July 28, 2010 Boston

  9. Beyond Antibodies Chapter 2 Antibody Sequence can be modified to make better Therapeutic Antibodies Antibodies Structure Structure-Function Correlation Evolution Terminology

  10. Changes in Amino acid sequence to improve function Cimzia Lucentis Medi-557 [Numax-YTE] Zevalin, Bexxar SGN-35, T-DM1 Antitope platform Elusys platform Teplizumab (MGA031; MacroGenics/Eli lilly)) otelixizumab (TRX4; Tolerx/GlaxoSmithKline)) Xencor, Biowa [MEDi-563], Potelligent, GA-101 [Glycart] Metmab; NatalizumabReslizumab (SCH55700; CeptionTherapeutics) NATURE REVIEWS | Immunology,Vol10 | MAY 2010 | pp 345-52

  11. Biosimilars – A Wall Street Perspective, RBC Capital Markets, LLC, Jason Kantor, Ph.D. (Analyst), May 26, 2011

  12. Beyond Antibodies Chapter 3 Antibody Drug Conjugates

  13. Pay Load Pay Load can be chemotherapeutic; radioisotope, cytokine, or a protein based toxin Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells

  14. Mechanism of Action of Chemolabelled ADCs NATURE REVIEWS | DRUG DISCOVERY, VOL 5 | FEB 2006 | pp- 147-159 HariHariharan, D.V.M., Ph.DAntibody Therapeutics Meeting December 9, 2010

  15. Chemolabelled ADCs

  16. Chemolabelled ADCs

  17. Radiolabelled ADCs Tositumomab and 131I tositumomab(Bexxar) Murine IgG2a/131I Anti-CD20 Indication - NHL refractory to Rituximab and relapsed following chemotherapy Ibritumomabtiuxetan [(Zevalin)], Murine IgG1/90Y Anti-CD20 Indication - Relapsed or refractory NHL http://canceres.info/?farmaco=ibritumomab-tiuxetan http://www.lymphomation.org/treatment-rit.htm http://cewilton.blogspot.in/2007_06_01_archive.html

  18. Cytokine-conjugated ADCs • EMD273066 [huKS-IL2 IC (EMD 273066) - IgG1 mAb specific for the human epithelial cell adhesion molecule (EpCAM) antigen, linked to two molecules of interleukin-2] • DI-Leu16-IL-2 [de-immunized and humanized anti-CD20 monoclonal antibody Leu16 fused to human cytokine interleukin-2 (IL2)] • F16–IL2 [Recombinant fusion protein composed of the antibody fragment scFv(F16) (specific to the alternatively spliced domain A1 of tenascin-C) and of human interleukin-2 (IL-2)] • hu14.18-IL2 (EMD 273063) - EMD Lexigen Research Center Corp [EMD-273063 is an antibody/cytokine fusion protein comprised of a humanized version of the murine anti-GD2 antibody 14.18 coupled to two molecules of IL-2] NATURE REVIEWS | DRUG DISCOVERY, VOL 5 | FEB 2006 | pp- 147-159

  19. ADCs in Development

  20. ADCs in Development

  21. Beyond Antibodies Chapter 4 Antibody Structure can be modified to make dramatically different Therapeutics Multispecific Antibody formats Types and Features BITE technology [Micromet] Antibody-ligand fusion proteins [Apoptosis inducing] Terminology

  22. Diverse variety of multi-specific antibody formats available Amino acids in the interface of CH3 domains, which form homodimersnaturally, are mutated at sites where two chains interact, such that one of them has a small side chain (hole), while the other has a large side chain (knob). The more favorable protein interaction between knobs and holes led to the almost exclusive heterodimerization of two different CH3 domains Two scFvs genetically fused to a human Immunoglobulin G (IgG), stability engineered, prokaryotic expression system and favourable biophysical properties Dual variable domain-Ig, multispecific, two antigen combining sites with different specificity in tandem on an IgG Germaine Fuh, Genentech, IBC Antibody Engineering 2009

  23. BiTE Technology Platform BiTE ;MT103 [Rabbit anti-CD19 scFv fragment x scFv fragment of a murine anti-CD3 mAb] rM28; [Murine anti-M-AP scFv fragment x scFV fragment of a murine anti-CD28 mAb] Patrick A. Baeuerle, Micromet, Inc. San Diego, December , 2009

  24. BiTE Technology – Mechanism of Action Blinatumomab (MT103; Micromet/Medimmune), a BiTE specific for CD19 and CD3 Patrick A. Baeuerle, Micromet, Inc. San Diego, December , 2009

  25. Bispecific Antibodies in Development Biosimilars – A Wall Street Perspective, RBC Capital Markets, LLC, Jason Kantor, Ph.D. (Analyst), May 26, 2011

  26. Beyond Antibodies Chapter 5 Non-Antibody Scaffolds – Natural proteins that are not antibodies but can work like them Alternative non-antibody scaffolds/Antibody mimetics Types and Features Characteristics Commercial scope

  27. Diverse Variety of Scaffolds can bind Antigens Company – Pieris Scaffold – Lipocalin Scaffold – variable lymphocyte receptors, Source - Jawless vertebrates Scaffold - Escherichia coli colicin E7 immunity protein Im7 Company – Adalta Scaffold – single domain antibody Source - Shark Company – Affibody Scaffold – Z domain of Protein A isolated from S.aureus Source - Bacteria Company - Molecular Partners-JnJ Scaffold – Ankyrin Source – Designed, synthetic Company – Adnexus Scaffold – Adnectin Company – Pieris Scaffold – Lipocalin Source - Human/insect Current Opinion in Pharmacology 2008, 8:609–615

  28. Diverse Antibody-like scaffolds in Development Prof Dr. Anne Skerra, Therapeutic Antibodies Europe 2010

  29. Desired properties and advantages over antibodies Prof Dr. Anne Skerra, Therapeutic Antibodies Europe 2010

  30. THANK YOU NATURE REVIEWS | DRUG DISCOVERY, VOL 5 | FEB 2006 | pp- 147-159

More Related